- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2016
- Public Summary Document (PSD) March 2016 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2016 PBAC Meeting - Word
Evolocumab – March 2016
Evolocumab: 140 mg/1 mL injection, 1 mL injection device, 1, Repatha®
Last updated
1 July 2016